Why the study?
Immune checkpoint inhibitor-associated myocarditis often presents with a severe phenotype and high fatality rate, while diagnosis remains challenging and treatment algorithms are still evolving.
This review summarizes current diagnostic and therapeutic algorithms for immune checkpoint inhibitor-related myocarditis and highlights the need for better risk stratification and multicenter registries.
No takes yet. Share an insight, caveat, or question.
Requires heightened vigilance for early ICI myocarditis given high fatality; leaves open standardized diagnostic and treatment algorithms.
Turker et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: